Close Menu

Friday, July 17

Browsing: ERHER2

Support

When to Replace Aromatase Inhibitors With SERDs in ER+/HER2– Advanced mBC

By NewsCancerJune 8, 20260

Results from the phase 3 persevERA trial (NCT04546009) showed that the use of first-line giredestrant plus palbociclib (Ibrance) showed a…

Support

FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer

By NewsCancerJune 3, 20260

The FDA has both accepted and granted priority review to a new drug application (NDA) for giredestrant as an adjuvant…

Treatments

Prosigna-Guided Adjuvant Therapy Shows Noninferiority in ER+/HER2– Breast Cancer

By NewsCancerMay 30, 20260

50-gene Prosigna assay-directed adjuvant therapy showed noninferior nvasive breast cancer–free survival (IBCFS) vs standard chemotherapy followed by endocrine therapy among…

Treatments

90 Real-World ESR1 Mutation and Testing Rates in Patients With ER+/HER2– Metastatic Breast Cancer

By NewsCancerMay 27, 20260

BackgroundAs the metastatic breast cancer treatment landscape evolves, understanding biomarker testing patterns is essential to identify patients for targeted therapies.…

Diagnosis

111 The Aurora Kinase A Inhibitor Alisertib Alone or in Combination With Endocrine Therapy for Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Metastatic Breast Cancer (MBC)

By NewsCancerMay 15, 20260

BackgroundAurora kinase A (AURKA) plays an integral role in the mitotic cell cycle, regulating spindle assembly, centrosome function, chromosome alignment,…

Survivors

TIP134 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From ER+/HER2– Breast Cancer

By NewsCancerMay 4, 20260

BackgroundEndocrine therapy (ET) plus CDK4/6 inhibitor (CDK4/6i) is the mainstay for the management of estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast…

Support

135 Elacestrant in Combination With Everolimus or Abemaciclib in Patients With ER+/HER2– Locally Advanced or Metastatic Breast Cancer (mBC): Phase 2 Results From ELEVATE, an Open-Label, Umbrella Study

By NewsCancerMay 3, 20260

BackgroundDisease progression in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer on first-line endocrine therapy (ET) plus CDK4/6 inhibitor…

Diagnosis

TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

By NewsCancerMay 2, 20260

BackgroundEndocrine therapy (ET) plus CDK4/6 inhibitor (CDK4/6i) is the standard-of-care (SOC) in first-line estrogen receptor–positive (ER+/HER2-negative (HER2–) advanced breast cancer;…

What's Hot

How Do Updated NCCN Guidelines and ctDNA Data Reshape MIBC Treatment?

Lauren Laverne diagnosed with blood disorder smouldering myeloma

Breast cancer detection and classification via a robust deep learning approach

Browsing: ERHER2

When to Replace Aromatase Inhibitors With SERDs in ER+/HER2– Advanced mBC

FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer

Prosigna-Guided Adjuvant Therapy Shows Noninferiority in ER+/HER2– Breast Cancer

90 Real-World ESR1 Mutation and Testing Rates in Patients With ER+/HER2– Metastatic Breast Cancer

111 The Aurora Kinase A Inhibitor Alisertib Alone or in Combination With Endocrine Therapy for Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Metastatic Breast Cancer (MBC)

TIP134 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From ER+/HER2– Breast Cancer

135 Elacestrant in Combination With Everolimus or Abemaciclib in Patients With ER+/HER2– Locally Advanced or Metastatic Breast Cancer (mBC): Phase 2 Results From ELEVATE, an Open-Label, Umbrella Study

TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

How Do Updated NCCN Guidelines and ctDNA Data Reshape MIBC Treatment?

Lauren Laverne diagnosed with blood disorder smouldering myeloma

Breast cancer detection and classification via a robust deep learning approach

Sequencing Treatment after EV-Pembro in Urothelial Carcinoma

How Do Updated NCCN Guidelines and ctDNA Data Reshape MIBC Treatment?

Lauren Laverne diagnosed with blood disorder smouldering myeloma

Breast cancer detection and classification via a robust deep learning approach

Sequencing Treatment after EV-Pembro in Urothelial Carcinoma

Latest Post

How Do Updated NCCN Guidelines and ctDNA Data Reshape MIBC Treatment?

Lauren Laverne diagnosed with blood disorder smouldering myeloma

Breast cancer detection and classification via a robust deep learning approach

Subscribe to Updates

What's Hot

Browsing: ERHER2